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Abstract
Mycoepoxydiene (MED) is a polyketide isolated from a marine fungus associated with mangrove forests. MED has been
shown to be able to induce cell cycle arrest and cancer cell apoptosis. However, its effects on inflammatory response are
unclear. Herein we showed that MED exhibited inhibitory effect on inflammatory response induced by lipopolysaccharide
(LPS). MED significantly inhibited LPS-induced expression of pro-inflammatory mediators such as tumor necrosis factor-
a (TNF-a), interleukin (IL)-1b, IL-6, and nitric oxide (NO) in macrophages. MED inhibited LPS-induced nuclear translocation of
nuclear factor (NF)-kB (NF-kB) p65, IkB degradation, IkB kinase (IKK) phosphorylation, and the activation of extracellular
signal-regulated kinase (ERK), c-jun N-terminal kinase (JNK), and p38, suggesting that MED blocks the activation of both NF-
kB and mitogen-activated protein kinase (MAPK) pathways. Furthermore, the effects of MED on LPS-induced activation of
upstream signaling molecules such as transforming growth factor-b–activated kinase 1 (TAK1), tumor necrosis factor
receptor-associated factor 6 (TRAF6) and IL-1 receptor associated kinases1 (IRAK1) were investigated. MED significantly
inhibited TAK1 phosphorylation and TRAF6 polyubiquitination, but not IRAK1 phosphorylation and TRAF6 dimerization,
indicating that MED inhibits LPS-induced inflammatory responses at least in part through suppression of TRAF6
polyubiquitination. Moreover, MED protected mice from LPS-induced endotoxin shock by reducing serum inflammatory
cytokines. These results suggest that MED is a potential lead compound for the development of a novel nonsteroidal anti-
inflammatory drug.
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Introduction
Lipopolysaccharide (LPS), an essential component of the outer
membrane of Gram-negative bacteria, can trigger host inflamma-
tory responses which are critical for host defense against bacterial
invasion [1,2]. However, overwhelming and uncontrolled in-
flammatory responses can lead to severe endotoxin shock and even
death [2]. Toll-like receptors (TLRs) recognize a variety of
pathogen-associated molecular patterns to initiate various signal-
ing pathways leading to inflammation [3]. LPS induces in-
flammatory responses via binding to TLR4 and triggering
cascades of intracellular signaling events to promote the secretion
of pro-inflammatory mediators including tumor necrosis factor-
a (TNF-a), interleukin (IL)-1b, IL-6, and nitric oxide (NO) [1,4].
These pro-inflammatory mediators play an important role in the
endotoxin shock and organ failure during inflammatory responses
[5].
It has been well demonstrated that nuclear factor-kB (NF-kB)
and mitogen-activated protein kinases (MAPKs) including extra-
cellular signal-regulated kinase (ERK), c-jun N-terminal kinase
(JNK), and p38 are major signaling pathways that mediate LPS-
induced inflammatory responses [6]. LPS-elicited activation of
NF-kB and MAPK pathways is initiated by the interaction
between myeloid differentiation factor 88 (MyD88) and Toll-like
receptor 4 (TLR4) upon LPS engagement. Then, MyD88 recruits
IL-1 receptor-associated kinases (IRAKs), tumor necrosis factor
receptor-associated factor 6 (TRAF6), and the transforming
growth factor-b-activated kinase 1 (TAK1) complex, leading to
early-phase activation of NF-kB and MAPKs [7]. NF-kB, an
important transcriptional factor, normally locates in the cytoplasm
forming an inactive complex with its inhibitory protein IkBa.
Upon stimulation, IkB kinase (IKK), which is activated by TAK1
complex, can phosphorylate IkBa. Subsequently, phosphorylated
IkBa is degraded by the proteasome to allow translocation of NF-
kB into the nucleus to initiate specific target gene transcription [8].
MAPKs, which are activated within the protein kinase cascades
consisting of three enzymes MAP kinase, MAP kinase kinase
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(MAP2K) and MAP kinase kinase kinase (MAP3K) [9], can
activate downstream transcription factors such as c-Jun, c-Fos,
ATF2, and Elk-1 to promote the expression of pro-inflammatory
mediators. Thus, blockage of the abovementioned signaling
pathways by small molecules represents a promising therapeutic
strategy for inflammation-associated diseases [10–13]. For exam-
ples, aspirin and salicylate target IKKb to suppress the initiation
and propagation of inflammation [14], specific inhibitors for ERK,
JNK and p38 pathways reverse inflammatory responses [11–13],
and TH-4-PX targets IRAK-1 to execute anti-inflammatory
action [15].
Mycoepoxydiene (MED), a novel polyketide containing an
oxygen-bridged cyclooctadiene core and an a, b-unsaturated
d lactone moiety [16], was isolated from the marine fungus
Diaporthe sp. (D. sp) HLY-1 found in submerged rotten leaves of
Kandelia candel in a mangrove forest in Fujian Province, China
[17]. A similar natural compound, whose biological function still
has not been described, was isolated from the fermentation broth
of OS-F66617, a fungal strain obtained from the deadwood of
forest in Brazil [18]. Previous studies showed that MED has
antimicrobial and anticancer activities [17,19]. In human cervical
cancer cell (Hela cell), MED maintains an anti-growth character-
istic through accelerating cytoskeletal rearrangement, inducing cell
cycle arrest in G2/M phase, prompting the activities of p38 and
JNK signaling pathways, and increasing the release of cytochrome
C as well as caspase-3 mediated cell apoptosis [19]. Despite some
biological significances of MED have been revealed, its effects on
inflammatory response are unclear. In this study, we demonstrated
that MED inhibited LPS-induced inflammatory responses through
blocking the activation of NF-kB and MAPK pathways via the
suppression of TRAF6 polyubiquitination. Additionally, MED
effectively prevented LPS-induced endotoxin shock in mice.
Results
MED strongly inhibits LPS-induced inflammatory
response in macrophages
MED is a novel polyketide containing an oxygen-bridged
cyclooctadiene core and an a, b-unsaturated d-lactone moiety
(Figure 1A). MED has been shown to be able to induce tumor cell
apoptosis [19]. However, MED had no apparent cytotoxicity to
murine macrophage cell lines RAW264.7 and primary peritoneal
macrophages at concentrations up to 10 mM in the absence or
presence of LPS (p.0.05, Figure 1B and C).
To examine whether MED can affect inflammatory response
induced by LPS, pro-inflammatory cytokines such as TNF-a, IL-
1b, and IL-6 were measured after LPS stimulation in the presence
or absence of MED. As shown in Figure 2A–F, the levels of TNF-
a, IL-1b, and IL-6 induced by LPS were significantly inhibited by
MED in a dose-dependent manner in RAW264.7 cells as well as in
primary peritoneal macrophages. Furthermore, MED could
significantly suppress the mRNA levels of TNF-a, IL-1b and IL-
6 induced by LPS (Figure 2G–I), indicating that MED inhibits
LPS-induced cytokine expression at the transcriptional level.
Nitric oxide (NO) is known to function as a pro-inflammatory
mediator in the pathogenesis of inflammation [20]. NO is
synthesized by nitric oxide synthases (NOS) including three
isozymes such as neuronal NOS (nNOS), endothelial NOS
(eNOS) and inducible NOS (iNOS). nNOS and eNOS are
constitutive NOS enzymes, iNOS is inducible and involved in
immune response by generating NO [21]. As shown in Figure 3A
and B, NO was induced in RAW264.7 cells as well as in primary
peritoneal macrophages after LPS treatment, but MED signifi-
cantly inhibited LPS-induced NO production at the concentra-
tions of 5 and 10 mM. Furthermore, the effect of MED on iNOS
expression induced by LPS was measured by real-time PCR and
Western blotting. As shown in Figure 3C, MED dose-dependently
inhibited LPS-induced expression of iNOS mRNA. Consistently,
MED suppressed LPS-stimulated iNOS protein production in
a dose-dependent manner (Figure 3D).
MED effectively suppresses LPS-induced NF-kB activation
NF-kB pathway plays an important role in regulating the
expression of pro-inflammatory factors such as TNF-a, IL-1b, IL-
6, and iNOS during inflammatory response. To investigate
whether the inhibition of pro-inflammatory factors by MED is
attributed to the suppression of this pathway, NF-kB dependent
promoter activity was examined in the presence or absence of
MED by using a luciferase reporter assay. As shown in Figure 4A,
MED significantly inhibited NF-kB luciferase reporter activity
induced by LPS in RAW 264.7 cells at the concentrations of 5 and
10 mM, suggesting that MED inhibits LPS-induced NF-kB
activation.
A series of upstream regulatory signaling factors such as IRAK1,
TRAF6, TAK1, and IKK mediate LPS-induced NF-kB activa-
Figure 1. Effect of MED on the viability of macrophages. A. Chemical structure of MED. B, C. RAW264.7 cells (B) and primary peritoneal
macrophages (C) were treated with various doses of MED in the presence or absence of LPS (100 ng/ml) for 24 h. Cell viability was determined as
described in the Methods. Data shown are the mean + SD (n = 3).
doi:10.1371/journal.pone.0044890.g001
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tion. Activated IKK can directly phosphorylate IkB, and then lead
to its degradation to allow translocation of NF-kB into the nucleus
to initiate target gene transcription [8]. Therefore, we examined
whether MED can suppress IKK activation and prevent IkBa
degradation by modulating LPS-induced IKK phosphorylation.
As shown in Figure 4B and C, MED inhibited LPS-induced IKK
phosphorylation and IkBa degradation in a dose-dependent
manner. Furthermore, we investigated the effect of MED on the
nuclear translocation of NF-kB. In the absence of MED, LPS
induced a significant nuclear translocation of p65 subunit of NF-
kB, but the amount of p65 translocated into the nucleus was
significantly reduced in the presence of MED (Figure 4D and E).
In addition, MED decreased LPS-induced DNA binding activity
of NF-kB at the concentrations of 5 and 10 mM (Figure 4F and
Figure S1). These results demonstrate that MED suppresses LPS-
induced NF-kB activation through inhibiting the activation of
IKK.
MED effectively suppresses LPS-induced activation of
MAPK pathways
In addition to NF-kB pathway, MAPK pathways which include
ERK, p38, and JNK are also involved in LPS-induced production
of inflammatory mediators in macrophages [6]. Therefore, the
effect of MED on the activation of MAPK pathways was examined
by detecting the phosphorylation of these kinases. As shown in
Figure 5A and B, MED significantly suppressed LPS-induced
phosphorylation of JNK, ERK1/2, and p38 in RAW264.7 cells as
well as in primary peritoneal macrophages at the concentrations of
Figure 2. MED inhibits the production of pro-inflammatory cytokines in RAW264.7 cells and primary peritoneal macrophages. A–F.
RAW264.7 cells (A–C) or peritoneal macrophages (D–F) were treated with LPS (100 ng/ml) together with various doses of MED or MED alone for 6 h.
The levels of TNF-a (A, D), IL-1b (B, E), and IL-6 (C, F) were determined using ELISA kits. Data shown are the mean + SD (n = 3). *p,0.05, **p,0.01. G-I.
RAW264.7 cells were treated with LPS (100 ng/ml) together with various doses of MED or MED alone for 4 h. The mRNA levels of TNF-a (G), IL-1b (H),
and IL-6 (I) were measured by real-time PCR. Data shown are the mean + SD (n = 3). * p,0.05, ** p,0.01.
doi:10.1371/journal.pone.0044890.g002
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5 and 10 mM, indicating that MED can suppress LPS-induced
activation of MAPK pathways.
Since TAK1 has been shown to be a pivotal factor for the
activation of IKK, JNK, and p38 in response to TLR stimulation
[22], and MED can suppress LPS-induced activation of IKK,
JNK, and p38, the effect of MED on the activation of TAK1 was
examined. As shown in Figure 5C, MED significantly inhibited
LPS-induced TAK1 activation at the concentrations of 5 and
10 mM, demonstrating that MED effectively suppresses the
activation of IKK, JNK and p38 through inhibiting the activation
of TAK1.
MED effectively suppresses LPS-induced
polyubiquitination of TRAF6
It has been reported that TRAF6 acts as an upstream regulator
of TAK1 in TLR4 signaling pathway. LPS induces phosphory-
lation of IRAK1 and then promotes interaction between IRAK1
and TRAF6, resulting in TRAF6 dimerization, which leads to Lys
63 polyubiquitination of target proteins including TRAF6 itself.
Ubiquitinated TRAF6 recruits TAB2 and activates the TAB2-
associated TAK1 kinase, which then phosphorylates and activates
IKK [23,24]. TRAF6 deficiency results in defective activation of
NF-kB and MAPK pathways [25], suggesting that TRAF6 is
essential for LPS-induced inflammatory response. Our result also
showed that TRAF6 knockdown could inhibit activation of NF-kB
and MAPK induced by LPS (Figure S2). Therefore, we in-
vestigated whether MED suppresses LPS-induced polyubiquitina-
tion of TRAF6. The results showed that MED markedly inhibited
LPS-induced TRAF6 polyubiquitination (Figure 6A). Further-
more, we examined the activation of IRAK1, which is required for
TRAF6 polyubiquitination, in response to LPS stimulation.
IRAK1 is activated by phosphorylation and then undergoes
proteasome-mediated degradation after LPS stimulation [26].
Phosphorylation of IRAK1 leads to a slower migrating band of
IRAK1 in SDS-PAGE [26,27]. As shown in Figure 6B, MED had
no significant effects on the phosphorylation of IRAK1 at 10, 20,
and 30 min after LPS treatment, although MED markedly
inhibited the degradation of IRAK1 at 30 min after LPS
treatment. In addition, we investigated whether MED could block
dimerization of TRAF6 in HEK 293T cells overexpressing
TRAF6. The result showed that MED did not affect TRAF6
dimerization (Figure 6C). Collectively, these results suggest that
MED inhibits LPS-induced inflammatory response through
blocking the polyubiquitination of TRAF6 independently on the
activation of IRAK1.
To determine whether MED can inhibit the ubiquitination of
TRAF6 independently on TLR4 signaling, we performed the
ubiquitination assays in 293T cells without LPS treatment. As
shown in Figure 7A, MED blocked the ubiquitination of TRAF6
in a dose-dependent manner. Furthermore, MED also markedly
suppressed the ubiquitination of TRAF6 in vitro ubiquitination
system (Figure 7B). These results indicate that MED may be
Figure 3. MED inhibits NO production and iNOS expression in RAW264.7 cells as well as in primary peritoneal macrophages. A, B.
RAW264.7 cells (A) or peritoneal macrophages (B) were treated with LPS (100 ng/ml) together with various doses of MED for 24 h. The level of NO
was determined using commercially available kit. Data shown are the mean + SD (n = 3). * p,0.05, ** p,0.01. C. RAW264.7 cells were treated with LPS
(100 ng/ml) together with various doses of MED for 6 h, and the mRNA levels of iNOS were measured by real-time PCR. Data shown are the mean +
SD (n = 3). ** p,0.01. D. RAW264.7 cells were treated with LPS (100 ng/ml) together with various doses of MED for 24 h, and the protein levels of
iNOS were determined by Western blotting.
doi:10.1371/journal.pone.0044890.g003
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a direct ubiquitination inhibitor for TRAF6 unbiquitination
process.
MED effectively protects mice from LPS-induced
endotoxin shock
The observations that MED effectively inhibited LPS-induced
inflammatory responses in vitro prompted us to investigate whether
MED can inhibit LPS-induced endotoxin shock in vivo. In the
absence of LPS, MED treatment did not affect the body
temperatures and serum cytokine levels in mice (Figure S3).
However, after 10 mg/kg LPS administration, the body temper-
ature of control mice markedly decreased and dropped to 22 uC at
30 h, indicating that mice suffer from severe LPS-induced
endotoxin shock. In contrast, pretreatment of MED effectively
suppressed the drop of body temperature caused by LPS
(Figure 8A). All mice administrated with LPS alone died within
72 h, but 80% of mice pretreated with MED survived and
recovered by the end of experiment (Figure 8B). Consistently,
MED significantly suppressed the levels of serum IL-1b and IL-6
(Figure 8C, D).
Furthermore, we detected the mRNA levels of IL-1b and IL-6
in the livers which contain many Kupffer cells (liver macrophages)
as well as in isolated peritoneal macrophages after treatment with
LPS with or without MED. As shown in Figure 8E–H, MED
inhibited the expression of these cytokines in the livers and in
isolated peritoneal macrophages after treatment with LPS,
confirming the inhibitory effects of MED on LPS-induced
inflammation is the result of inhibition of macrophage cytokine
expression in vivo.
Discussion
MED, a novel polyketide, was isolated from the marine fungus
D. sp. HLY-1 found in submerged rotten leaves of Kandelia candel in
a mangrove forest [17]. Previous studies showed that MED has
antimicrobial and anticancer activities [17,19]. In the present
study, we showed that MED not only markedly inhibited LPS-
induced inflammatory response in cultured macrophages, but also
suppressed septic shock induced by LPS in vivo, demonstrating that
MED has an anti-inflammatory activity.
Stimulation of TLR4 by LPS activates intracellular signaling
events such as IKK/NF-kB and MAPK pathways to induce the
production of various inflammatory mediators [6]. MAPKs belong
to a highly conserved family of protein serine/threonine kinases
Figure 4. MED suppresses LPS-induced NF-kB activation in RAW264.7 cells. A. Effect of MED on NF-kB luciferase reporter activity after LPS
treatment. Cells were transiently transfected with NF-kB luciferase reporter plasmids and incubated overnight, then cells were treated with LPS
(100 ng/ml) together with various doses of MED for 6 h. Luciferase activities were determined as described in the Methods. Data shown are the mean
+ SD (n = 3). **p,0.01. B. Effect of MED on phosphorylation of IKK induced by LPS. Cells were treated with LPS (100 ng/ml) together with various
doses of MED for 10 min. C. Effect of MED on degradation of IkBa induced by LPS. Cells were treated by LPS (100 ng/ml) together with various doses
of MED for 15 min. D, E. Effect of MED on nuclear translocation of NF-kB p65 induced by LPS. Cells were treated by LPS (100 ng/ml) together with
various doses of MED for 30 min, then nuclear translocation of p65 was determined by Western blotting (D) or Immunofluoresence analysis (E). C:
Cytoplasm; N: Nucleus. The area of nucleus was marked with PI. F. Effect of MED on DNA binding activity of NF-kB induced by LPS. Cells were treated
with LPS (100 ng/ml) together with various doses of MED for 30 min. Nuclear extracts were obtained for EMSA.
doi:10.1371/journal.pone.0044890.g004
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including p38, JNK and ERK1/2, whereas IKK is a kinase for
NF-kB activation. Suppression of the activation of p38, JNK,
ERK1/2, and IKK by MED suggests that MED could affect
upstream signaling of IKK and MAPKs. TAK1, a member of the
MAP3K family, is known to act as a key modulator of IKK
pathway as well as p38 and JNK cascades [22]. MED suppressed
the activation of TAK1 induced by LPS, indicating that MED
negatively affects IKK, p38, and JNK pathways through blocking
the activation of TAK1.
Binding of LPS to TLR4 results in recruitment of MyD88 to the
membrane, and then promotes the assembly of a proximal
signaling complex that includes IRAK1, IRAK4 and TRAF6,
which facilitates the phosphorylation of IRAK1 by IRAK4
[28,29]. Phosphorylated activation of IRAK1 promotes dissocia-
tion of IRAK1 and TRAF6 from TLR4. Activated IRAK1 is
ubiquitinated and eventually degraded by the proteasome, which
serves as a negative feedback mechanism of down-regulating IL-
1R/TLR-mediated signaling and cytokine gene transcription [30].
The dimerization of TRAF6 catalyzes the formation of a poly-
ubiquitin chain linked through Lys63, which is required for
activation of TAK1 in LPS-induced cellular responses [23]. MED
suppressed the polyubiquitination of TRAF6, but did not affect
TRAF6 dimerization and IRAK1 phosphorylation, suggesting
that TRAF6 could be the target of MED in response to LPS.
Ubiquitination plays an important role in regulation of TLR
signaling pathway including positive and negative feedback [23].
Figure 5. MED suppresses LPS-induced MAPK activation. A, B.
RAW264.7 cells (A) and primary peritoneal macrophages (B) were
treated with LPS (100 ng/ml) together with various doses of MED for
20 min. The phosphorylation of MAPKs including JNK, ERK1/2 and p38
was determined by Western blotting analysis. C. Effect of MED on
phosphorylation of TAK1 induced by LPS in RAW264.7 cells. Cells were
treated with LPS (100 ng/ml) together with various doses of MED for
10 min.
doi:10.1371/journal.pone.0044890.g005
Figure 6. MED suppresses TRAF6 polyubiquitination but not
IRAK1 phosphorylation and TRAF6 dimerization. A. Effect of
MED on polyubiquitination of TRAF6 induced by LPS in RAW264.7 cells.
Cells were treated with LPS (100 ng/ml) together with various amounts
of MED for 10 min. The cell lysates were immunoprecipitated by TRAF6
antibodies or isotype IgG, and then TRAF6 polyubiquitination was
determined by Western blotting. B. Effect of MED on activation of IRAK1
induced by LPS in RAW264.7 cells. Cells were treated by LPS (100 ng/ml)
together with MED (10 mM) for different times. The non-phosphorylated
and phosphorylated IRAK1s (active form) were detected by Western
blotting. ** p,0.01. C. Effect of MED on dimerization of TRAF6 in HEK
293T cells overexpressing TRAF6. The cells were transfected with Myc-
TRAF6 expression plasmids and incubated overnight, then the cells
were treated with various doses of MED for 4 h. Cell lysates were
analyzed by native gel and denature gel.
doi:10.1371/journal.pone.0044890.g006
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MED inhibited not only polyubiquitination of TRAF6 but also
polyubiquitination-mediated degradation of IRAK1 and IkBa
induced by LPS, implicating that MED may serve as an
ubiquitination inhibitor to inhibit the ubiquitination of proteins
involved in TLR4 pathway. Indeed, we found that MED
significantly blocked the ubiquitination of TRAF6 and IkBa
(Figure 7A and Figure S4) in HEK 293T cells without LPS
treatment, indicating that MED can inhibit protein ubiquitination
independently on TLR4 signaling. The mechanism by which
MED inhibits protein ubiquitination is currently under investiga-
tion.
Collectively, in this study, we demonstrate that MED, as a novel
marine microbial compound, can not only effectively inhibit LPS-
induced inflammatory response through the suppression of
TRAF6 polyubiquitination (Figure 9), but also alleviate LPS-
induced endotoxin shock in vivo, suggesting that MED is a potential
lead compound for the development of novel anti-inflammatory
drugs, and marine microbial bioactive compounds may be an
important source of new anti-inflammatory drugs.
Materials and Methods
Materials
LPS (Escherichia coli strain O111:B4) was obtained from Sigma
(St Louis, MO, USA). MED was isolated from the fermentation
broth of D. sp. HLY-1 as described [17]. The identity of MED was
confirmed by HRMS, 1H and 13C NMR analysis, as reported by
Lin et al. [17]. The purity of MED exceeded 95.7% according to
the HPLC analysis (Figure S5). A 10 mM stock solution in DMSO
was prepared and stored at 220 uC. Antibodies against phospho-
p38, p38, phospho-JNK, JNK, phospho-ERK 1/2, ERK 1/2,
phospho-IKKa/b, IKKb, phospho-Akt, Akt, phospho-TAK1 and
IRAK1 were purchased from Cell Signaling Technology (Dan-
vers, MA, USA). Antibodies against IkBa, p65, inducible NO
synthase (iNOS), PARP, a-tubulin, TAK1, TRAF6 and ubiquitin
(Ub) were obtained from Santa Cruz Biotechnology (Santa Cruz,
CA, USA). b-actin antibody was purchased from Sigma. Female
BALB/c mice (6–8 weeks age) were used for all experiments.
Animals were maintained with specific pathogen free air at
a temperature between 20 and 23 uC with 12 h light and dark
cycles and relative humidity of 50%. Animal experiments were
performed in accordance with the Guide for the Care and Use of
Laboratory Animals. All animal experimental procedures were
approved by Animal Care and Use Committee of Xiamen
University (Protocol Number: XMULAC20120001). Every effort
was made to reduce the suffering of animals.
Cell culture and transfection
Murine macrophage cell line RAW264.7 cells and human
embryonic kidney cell line HEK293T were purchased from the
American Type Cell Culture Collection. Peritoneal macrophages
were obtained from mice after three days’ 4% Thioglycollate
medium (Sigma) induction. All cell lines were cultured in DMEM
supplemented with 10% fetal bovine serum (FBS). Cells were
transfected with different plasmids using lipofectamine 2000
(Invitrogen, Carlsbad, CA) and with siRNA (100 nM) using
TransIT-TKO transfection reagent (Mirus, Madison, WI) accord-
ing to the manufacturer’s instructions. The TRAF6-specific siRNA
were 59-ACCACGAAGAGGUCAUGGA-39 (sense) and 59-UC-
CAUGACCUCUUCGUGGU-39 (antisense).
Cell viability assay
Cell viability was analyzed by MTT assay. A total of 86104 cells
were seeded in 96 well plates. After incubation of 24 h, 10 ml
MTT (5 mg/ml, Sigma) was added to each well. The plates were
incubated for 4 h before addition of 100 ml lysis buffer (10% SDS
in 0.01 M HCl). The absorbance was measured at 560 nm using
a microplate reader.
Cytokine assay
Cells were seeded in 96 well plates 24 h prior to LPS and MED
treatment. After added with LPS or LPS plus MED, cells were
further cultured for 6 h. The concentrations of TNF-a, IL-1b, and
IL-6 were determined using ELISA kits (eBioscience, San Diego,
CA) according to the manufacturer’s instructions.
Nitrite measurement
Cells were seeded in 96 well plates 24 h prior to LPS and MED
stimulation. After addition LPS or LPS plus MED, cells were
further cultured for 24 h. The concentration of NO was de-
termined by commercially available kit (Nanjing Jiancheng
Bioengineering Institute, Nanjing, China) according to the
manufacturer’s instruction.
Figure 7. Effect of MED on the ubiquitination of TRAF6 in vivo
and in vitro. A. HEK 293T cells were transfected with Myc-TRAF6 and
HA-Ub expression plasmids and incubated overnight, then cells were
treated with various doses of MED for 4 h. Cell lysates were
immunoprecipitated and analyzed by Western blotting. B. MED
inhibited the ubiquitination of TRAF6 in vitro ubiquitination assay.
HEK 293T cells were transfected with Myc-TRAF6 expression plasmids
and incubated overnight, and then cell lysates were immunoprecipi-
tated by TRAF6 antibodies for 3 h. Then the beads were washed three
times using IP buffer and twice using TBS buffer. The beads were pre-
treated with various doses of MED for 30 min on ice and then subjected
to in vitro ubiquitination assay.
doi:10.1371/journal.pone.0044890.g007
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Luciferase reporter assay
Cells were harvested 24 h after transfection and luciferase
activity was assayed and normalized to Renilla luciferase activity
using a dual luciferase reporter assay system (Promega, Madison,
WI).
Nuclear protein extraction
After LPS and MED treatments, cells were collected and added
with Buffer A (10 mM Hepes (pH 7.9), 10 mM KCl, 0.1 mM
EDTA, 1 mM DTT, and 0.5 mM PMSF). After incubated in ices
for 20 min, cells were added with Buffer A with 2.5% NP- 40 and
Figure 8. MED protects mice from LPS-induced endotoxin shock. A. BALB/c mice were divided in two groups (n = 10 for each group), one
group was only i.p. injected with LPS (10 mg/kg); another group was pre-injected with MED (15 mg/kg) for 30 min before LPS injection. Body
temperatures of two groups of mice were measured at different time points. B. Survival rates of mice were examined after LPS administration with or
without MED pretreatment. C, D. The levels of IL-1b (C) and IL-6 (D) in serum were measured at 8 h after LPS injection with or without MED
pretreatment. *p,0.05, **p,0.01. E, F. MED reduced the mRNA levels of IL-1b and IL-6 in the liver of mice after LPS treatment. G, H. MED reduced the
mRNA levels of IL-1b and IL-6 in peritoneal macrophages isolated from mice treated with LPS.
doi:10.1371/journal.pone.0044890.g008
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vibrated for 10 sec and then centrifuged at 12000 g for 5 min at 4
uC, the supernatants were collected to detect proteins located in
cytoplasm. Buffer B(20 mM Hepes (pH 7.9), 0.4 M NaCl, 1 mM
EDTA, 1 mM DTT, 1 mM PMSF)was added to the precipitates
and vibrated for 25 min at 4 uC and then centrifuged at 12000 g
for 5 min at 4 uC, the supernatants were collected as nuclear
extracts, and the protein concentration was measured by Bradford
protein assay (Bio-Rad, Hercules, CA).
Immunofluoresence for NF-kB p65 localization
Cells were treated with LPS and MED for 30 min and then
fixed with 4% paraformaldehyde for 15 min. After penetrated
with 0.3% Triton X-100 in PBS for 10 min, cells were blocked
with 5% bovine serum albumin for 30 min and incubated with
Rabbit polyclonal anti-p65 antibodies for 2 h. Then, cells were
incubated with Fluorescein-conjugated Goat anti-Rabbit IgG for
1 h and counterstained with propidium iodide (PI) for 5 min.
Stained slides were mounted with mounting medium and analyzed
under a laser confocal fluorescence microscopy (Leica, Heidelberg,
Germany).
Electrophoretic mobility shift assay
Five mg of nuclear extract was incubated with 20 nM biotin-
labeled double strands oligonucleotide probes for 20 min at room
temperature and then separated on a non-denaturing 6% (w/v)
polyacrylamide gel. The biotin-labeled oligonucleotide probes
were transferred from the polyacrylamide gel onto a nylon
membrane and then detected with LightShift chemiluminescent
EMSA kit (Pierce, Rockford, IL) according to the manufacturer’s
instruction.
Quantitative real-time PCR
Total RNA was isolated with Trizol reagent (Invitrogen)
according to the manufacturer’s instructions. The cDNA was
synthesized from 2 mg of total RNA using MMLV transcriptase
(ToYoBo, Shanghai, China) with random hexamers. Real-time
PCRs were performed using SYBR Premix ExTaq (TaKaRa,
Dalian, China). Relative quantification was achieved by normal-
ization to the amount of TBP. Primers used for real-time PCR are
listed on Table 1.
Immunoprecipitation and immunoblotting analysis
Cells were lysed with lysis buffer (200 mM Tris-HCl (pH 7.5),
1.5 M NaCl, 10 mM EDTA, 25 mM sodium pyrophosphate,
10 mM glycerolphosphate, 10 mM sodium orythovanadate,
50 mM NaF, 1 mM PMSF, in combination with protein inhibitor
cocktail). Total cell lysates were incubated with the indicated
antibodies in combination with protein A/G beads (Santa cruz) for
3h. The complexes were washed five times with cell lysis buffer.
The samples were subjected to SDS-PAGE and transferred onto
nitrocellulose membranes. Blots were probed with the specific
primary antibodies. After extensive washing, blots were then
incubated with horseradish peroxidaseconjugated secondary anti-
body (Pierce) and visualized by chemiluminescence.
Native PAGE
A 10% Native gel was pre-run with 25 mM Tris and 192 mM
glycine for 30 min at 40 mA. Samples in the native sample buffer
(62.5 mM Tris-HCl, pH 6.8, 20% glycerol, 0.02% Bromophenol
Blue) were applied to the gel and electrophoresed at 25 mA at 4
uC until the bromophenol blue dye front reach the bottom of the
gel. This was followed by Western blotting with the indicated
antibodies.
In Vitro Ubiquitination Assay
HEK 293T cells were transfected with Myc-TRAF6 and
incubated overnight. Then TRAF6 was immunopurified with
anti-TRAF6 and proteinA/G-Sepharose beads from HEK 293T
cell lysates. Then the autoubiquitination assay was performed in
a 50 mL reaction volume. Briefly, the immunoprecipitated TRAF6
Figure 9. Schematic representation of the mechanism by which MED inhibits LPS-induced inflammatory responses in
macrophages. MED blocks LPS-induced polyubiquitination of TRAF6 and then inhibits the activation of TAK1 and IKK, leading to the inhibition
of multi-signaling cascades including NF-kB and MAPKs such as p38, JNK and ERK, that in turn leads to inhibition of cytokine/iNOS induction. In
addition, MED may be involved in regulating the ubiquitination and degradation of other proteins such as IRAK1 and IkBa to affect LPS signaling.
doi:10.1371/journal.pone.0044890.g009
Table 1. Primers for real-time PCR.
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was preincubated with various does of MED on ice for 30 min,
and then 0.15 mg of recombinant E1-activating enzyme, 1 mg of
Ubc13/Uev1a-conjugating complex, and 2.5 mg of ubiquitin were
added. Four mM ATP was added to initiate the reaction, and the
mixtures were incubated at 30 uC for 1 h with gentle agitation.
Then the reaction was blocked by loading buffer and then the
samples were subjected to immunoblotting with the indicated
antibodies.
LPS-induced endotoxin shock
Mice were i.p. pretreated with DMSO or MED (15 mg/kg) for
30 min and then i.p. injected with LPS (10 mg/kg). Body
temperatures of mice were measured at 1, 4, 6, 10, and 24 h
after LPS injection, respectively; meanwhile, the survival rates of
mice were recorded at 12, 24, 36, 48, 60, and 72 h post-injection.
For serum cytokine assay, mice were anesthetized and sacrificed at
8 h after LPS injection, and whole bloods of mice were collected
and centrifuged to obtain serum. For cytokine mRNA assay, mice
were pretreated with MED for 30 min, and then liver and
peritoneal macrophages were collected for harvesting mRNA at
2 h after LPS injection.
Statistical analysis
Data were collected from several independent experiments, with
three replicates per experiment. All data were analyzed with two-
tailed Student’s t test in SPSS 11.0 and p,0.05 was considered
statistically significant. Bars in the graph represent standard
deviation (S.D.).
Supporting Information
Figure S1 MED suppresses DNA binding activity of NF-
kB induced by LPS.
(TIF)
Figure S2 The effect of TRAF6 knockdown on activation
of NF-kB and MAPK induced by LPS.
(TIF)
Figure S3 MED alone has no effect on body tempera-
tures and cytokine levels in mice.
(TIF)
Figure S4 Effect of MED on the ubiquitination of IkBa in
HEK 293T cells.
(TIF)
Figure S5 HPLC analysis for the purity of MED.
(TIF)
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